RETAANE: what does the future hold?

Article

Alcon has received an approvable letter from the FDA for RETAANE 15 mg (anecortave acetate depot suspension) for the treatment of wet age-related macular degeneration (AMD), however the letter advised that an additional clinical study would be required before approval is given.

Alcon has received an approvable letter from the FDA for RETAANE 15 mg (anecortave acetate depot suspension) for the treatment of wet age-related macular degeneration (AMD), however the letter advised that an additional clinical study would be required before approval is given.

In light of this, Alcon has decided not to proceed with the process, but it will continue with the Anecortave Acetate Risk-Reduction Trial (AART), which is investigating the ability of RETAANE to reduce the risk for the progression of dry AMD to wet AMD.

The trial has already completed enrolment and is expected to conclude within three years.

Related Videos
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
Dr Mary Elizabeth Hartnett speaks with David Hutton of Ophthalmology Times
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
© 2023 MJH Life Sciences

All rights reserved.